A clinical trial listing involving somatostatin was updated on October 30, 2026. The trial, titled "PDMC Implementation Trial in Kenya" and registered as NCT06624631, is listed with a phase designation of not applicable. Its status was recorded as completed as of this date. Somatostatin remains classified as an unapproved compound for research use.
The trial record does not include results data in the information provided. No outcome measures, efficacy findings, or safety signals are described in this update. The completion status reflects only that the trial has concluded its planned activities, not that specific results have been published or analyzed.
This update is based solely on the status change recorded in the trial registry. No additional details about trial design, population, or endpoints are included here beyond what has been stated. Readers interested in the full trial record can consult the official registry listing for further specifics, including any future results postings.
For more background on somatostatin, including its research status and general profile, readers can refer to the compound overview.